Quantcast

Latest Beta amyloid Stories

2014-07-13 12:20:48

Study Results Presented at the Alzheimer's Association International Conference 2014 INDIANAPOLIS, July 13, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced results from its non-clinical study in genetically engineered mice examining combination therapy with the murine version of the beta-amyloid antibody N3pG and beta-secretase inhibitor BACE (LY2811376). Data results found that combination therapy was more effective in removing clumps of amyloid-beta protein...

2014-07-13 04:20:20

New Alzheimer's biomarker results reported at Alzheimer's Association International Conference 2014 COPENHAGEN, Denmark, July 13, 2014 /PRNewswire-USNewswire/ -- A decreased ability to identify odors might indicate the development of cognitive impairment and Alzheimer's disease, while examinations of the eye could indicate the build-up of beta-amyloid, a protein associated with Alzheimer's, in the brain, according to the results of four research trials reported today at the...

2014-07-08 08:30:45

Highlights include additional analyses from Phase 3 and ongoing open-label studies, discovery research on the potential use of combination therapy and data on the impact of beta-amyloid imaging on diagnosis and management INDIANAPOLIS, July 8, 2014 /PRNewswire/ -- Eli Lilly and Company (NYSE: LLY) today announced that 23 presentations will be given at the Alzheimer's Association International Conference 2014 (AAIC 2014) in Copenhagen, Denmark from July 12 - 17, 2014. Of particular interest...

Specific Mechanisms Of Alzheimer’s Disease Countered By Cocoa Extract
2014-06-24 03:38:45

Mount Sinai Hospital Insights into mechanisms behind cocoa’s benefit may lead to new treatments or dietary regimens A specific preparation of cocoa-extract called Lavado may reduce damage to nerve pathways seen in Alzheimer’s disease patients’ brains long before they develop symptoms, according to a study conducted at the Icahn School of Medicine at Mount Sinai and published June 20 in the Journal of Alzheimer’s Disease (JAD). Specifically, the study results, using mice...

2014-05-28 08:26:44

- Preclinical data demonstrates reduction of Alzheimer's brain deficits to lower toxic Amyloid-beta and restored synaptic loss - PLANTATION, Fla., May 28, 2014 /PRNewswire/ -- Neurotrope, Inc. (OTCQB: NTRP) announced today the publication of positive human cell culture and mouse model data of Bryostatin 1 in two peer reviewed journals: PLOS One and the Journal of Pharmacology and Experimental Therapeutics. Neurotrope's lead drug candidate, Bryostatin 1, a potent activator of the...

2014-05-27 23:06:05

MetLife Foundation has announced the recipients of the 2014 MetLife Foundation Awards for Medical Research: Riqiang Yan, Ph.D., vice chair of the Department of Neurosciences, Lerner Research Institute, Cleveland Clinic; and Lary C. Walker, Ph.D., research professor of neuropharmacology and neurologic diseases and associate professor of neurology, Yerkes National Primate Research Center, Emory University (Atlanta, GA) and Mathias Jucker, Ph.D., full professor, Hertie Institute for Clinical...

2014-05-21 16:27:02

PITTSBURGH, May 21, 2014 /PRNewswire/ -- Cognition Therapeutics Inc. (CogRx), an innovative research and drug discovery organization focused on the development of novel disease-modifying therapeutics for neurodegenerative diseases, announced today that its small molecule soluble Abeta receptor antagonist program for the treatment of Alzheimer's disease (AD) has been selected for funding by the National Institute on Aging (NIA)/NIH Alzheimer's Disease Drug Development Program (U01)....

2014-05-21 11:48:44

Saint Louis University A molecular compound developed by Saint Louis University scientists restored learning, memory and appropriate behavior in a mouse model of Alzheimer's disease, according to findings in the May issue of the Journal of Alzheimer's Disease. The molecule also reduced inflammation in the part of the brain responsible for learning and memory. The paper, authored by a team of scientists led by Susan Farr, Ph.D., research professor of geriatrics at Saint Louis University,...

2014-04-30 12:30:34

Data Highlight Physician and Payer Expectations for New Symptomatic and Disease-Modifying Therapies, According to Findings from Decision Resources Group BURLINGTON, Mass., April 30, 2014 /PRNewswire/ -- Decision Resources Group finds that surveyed U.S. neurologists are particularly receptive to novel symptomatic agents and would prescribe Lundbeck/Otsuka's selective 5-HT6 receptor antagonist Lu-AE58054 to a median 25 percent of their drug-treated mild to moderate Alzheimer's disease patients,...

2014-04-22 12:09:23

Research published in the Journal of Molecular Biology Researchers from NeuroPhage Pharmaceuticals, Inc. have engineered a series of molecules with the potential to treat most neurodegenerative diseases that are characterized by misfolded proteins, such as Alzheimer's, Parkinson's and Huntington's diseases. These molecules are based on what the Company calls a general amyloid interaction motif, or GAIM, which recognizes a characteristic common to many toxic, misfolded proteins, not just...


Word of the Day
cacodemon
  • An evil spirit; a devil.
  • A nightmare.
  • In astrology, the twelfth house of a scheme or figure of the heavens: so called from its signifying dreadful things, such as secret enemies, great losses, imprisonment, etc.
'Cacodemon' comes from a Greek term meaning 'evil genius.'
Related